Abstract
Objective:To analyze the clinical values of modified injection of low-molecular-weight heparin in reducing subcutaneous bleeding and pain.Methods:Two hundred and sixty patients with cerebral infarction, acute myocardial infarction or pulmonary embolism who underwent subcutaneous injection of low-molecular weight heparin in the hospital between December 2015 and December 2016 were selected. They were randomly divided into a control group and a research group, 130 each. Patients in the control group were given conventional injection, while patients in the research group were given modified injection. The occurrence of subcutaneous bleeding and pain was observed and compared between the two groups.Results:The incidence of subcutaneous hemorrhage in the research group was 46.9%, significantly lower than 83.1% in the control group, and the difference had statistical significance (P<0.05). Twenty-six patients in the control group had severe pain, which was much more than 5 patients in the research group, and the difference was statistically significant (P<0.05). The number of cases of severe hemorrhage in the control group was significantly larger than that of the research group (31 vs. 3), and the difference was also statistically significant.Conclusion:Modified low-molecular weight heparin injection can effectively reduce the incidence of bleeding and pain, which is beneficial to the compliance and quality of life of elder patients.
Highlights
Low-molecular-weight heparin, a novel anticoagulant developed in 1970s, has similar pharmacological effects with ordinary heparin sodium
The main application mode of low molecular heparin is subcutaneous injection and intravascular injection is used in hematodialysis
Subcutaneous bleeding at injection sites is a common adverse reaction of subcutaneous injection of low molecular heparin, with an incidence of 90%
Summary
Low-molecular-weight heparin, a novel anticoagulant developed in 1970s, has similar pharmacological effects with ordinary heparin sodium. It has advantages of high bioavailability, strong antithrombotic effect, long half-life period and low incidence of bleeding compared with ordinary heparin.[1,2] it has been extensively applied to prevent and treat various thromboembolic diseases.[3] Currently the main application mode of low molecular heparin is subcutaneous injection and intravascular injection is used in hematodialysis. Subcutaneous bleeding at injection sites is a common adverse reaction of subcutaneous injection of low molecular heparin, with an incidence of 90%.4. Subcutaneous bleeding at injection sites is a common adverse reaction of subcutaneous injection of low molecular heparin, with an incidence of 90%.4 It is associated with
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
